Osteoporosis is a growing epidemic that leads to significant morbidity and mortality among the elderly population due to associated fractures that lead to disabilities and reduced quality of life. Bisphosphonates are well-established as a first-line and cost-effective treatment for osteoporosis. Unfortunately, clinicians are often uncertain as to how to select treatments when bisphosphonates are ineffective as initial treatment or contraindicated. Romosozumab and abaloparatide are 2 alternative agents that have been recently FDA approved for the treatment of osteoporosis in postmenopausal women at high risk for fracture or patients who have failed or are intolerant to other osteoporosis therapies. Currently, the National Osteoporosis Foundation (NOF) has no formal recommendations in regard to these 2 novel agents. The purpose of this review is to help guide pharmacists on how to ensure appropriate utilization of these 2 novel bone-forming agents as potential alternatives to bisphosphonate therapy by providing evidence-based recommendations according to the current literature and key counseling points.
BurgeRDawson HughesBSolomonDHJohnBWAlisonKAnnaT. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–475.
2.
PanulaJPihlajamäkiHMattilaVM, et al.Mortality and cause of death in hip fracture patients aged 65 or older-a population-based study. BMC Musculoskel Disord. 2011;12(1):105.
3.
OdénAMcCloskeyEVJohanssonHJohnAK. Assessing the impact of osteoporosis on the burden of hip fractures. Calcif Tissue Int. 2013;92(1):42–49.
4.
GullbergBJohnellOKanisJA. World-wide projections for hip fracture. Osteoporos Int. 1997;7(5):407–413.
5.
CooperCCampionGMeltonLJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2(6):285–289.
6.
JordanKMCooperC. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol. 2002;16(5):795–806.
7.
KalkımADağhanS. Theory-based osteoporosis prevention education and counseling program for women: a randomized controlled trial. Asian Nurs Res. 2017;11(2):119–127.
8.
ShinHYKangHCLeeK, et al.Association between the awareness of osteoporosis and the quality of care for bone health among Korean women with osteoporosis. BMC Musculoskel Disord. 2014;15(1):334.
9.
SpencerSJ. Lack of knowledge of osteoporosis: a multi-centre, observational study. Scott Med J. 2007;52(1):13–16.
10.
EliasMNBurdenAMCadaretteSM. The impact of pharmacist interventions on osteoporosis management: a systematic review. Osteoporos Int. 2011;22(10):2587–2596.
11.
CosmanFde BeurSJLeBoffMS, et al.Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381.
12.
WangZWardMMChanLBhattacharyyaT. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female Medicare beneficiaries. Osteoporos Int. 2014;25(8):2109–2116.
13.
KhanSNCraigLWildR. Osteoporosis: therapeutic guidelines. Guidelines for practice management of osteoporosis. Clin Obstet Gynecol. 2013;56(4):694–702.
SaagKGPetersenJBrandiML, et al.Romosozumab or alendronate for fracture prevention in women with osteoporosis. New Engl J Med. 2017;377(15):1417–1427.
16.
MillerPDHattersleyGRiisBJ, et al.Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722–733.
17.
NeerRMArnaudCDZanchettaJR, et al.Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441.
18.
CummingsSRMartinJSMcClungMR, et al.Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765.
19.
ChesnutCHSilvermanSAndrianoK, et al.A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med. 2000;109(4):267–276.
20.
EttingerBBlackDMMitlakBH, et al.Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282(7):637–645.
21.
BlackDMCummingsSRKarpfDB, et al.Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348(9041):1535–1541.
22.
ChestnutCHSkaAChristiansenC, et al.Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241–1249.
23.
HarrisSTWattsNBGenantHK, et al.Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282(14):1344–1352.
24.
Colon-EmericCSCaminisJSuhTT, et al.The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin. 2004;20(6):903–910.
LederBZTsaiJNJiangLAHangL. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: the denosumab and teriparatide follow-up study (DATA-Follow-up). Bone. 2017;98:54–58.
29.
BoneHGCosmanFMillerPD, et al.ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab. 2018;103(8):2949–2957.
CamachoPMPetakSMBinkleyN, et al.American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update. Endocr Pract. 2020;26(Suppl 1):1–46.
RosenCJGallagherJC. The 2011 IOM report on vitamin D and calcium requirements for North America: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom. 2011;14(2):79–84.
42.
SunyeczJA. The use of calcium and vitamin D in the management of osteoporosis. Ther Clin Risk Manag. 2008;4(4):827–836.
43.
RossACMansonJEAbramsSA, et al.The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96(1):53–58.
44.
PiercyKLTroianoRPBallardRM, et al.The physical activity guidelines for Americans. JAMA. 2018;320(19):2020–2028.
45.
KraussRMEckelRHHowardB, et al.AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the nutrition committee of the American heart association. Circulation. 2000;102(18):2284–2299.
46.
Appleman-DijkstraNMPapapoulosSE. Clinical advantages and disadvantages of anabolic bone therapies targeting the WNT pathway. Nat Rev Endocrinol. 2018;14(10):605–623.
47.
LimSYBolsterMB. Profile of romosozumab and its potential in the management of osteoporosis. Drug Des Dev Ther. 2017;11:1221–1231.
48.
McClungMRGrauerABoonenS, et al.Romosozumab in postmenopausal women with low bone mineral density. New Engl J Med. 2014;370(5):412–420.
49.
PradiDJangGStouchBLiangFEdwardP. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26.
50.
HattersleyGDeanTCorbinBAHilaBThomasJG. Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling. Endocrinology. 2016;157(1):141–149.
51.
BoyceEGMaiYPhamC. Abaloparatide: review of a next-generation parathyroid hormone agonist. Ann Pharmacother2018;52(5):462–472.
52.
CosmanFHattersleyGHuMYGregoryCWLorraineAFDennisMB. Effects of abaloparatide-SC on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors. J Bone Miner Res. 2017;32(1):17–23.
53.
RittmasterRSBologneseMEttingerMP, et al.Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000;85(6):2129–2134.
54.
Active ingredient: Abaloparatide. RED BOOK Online. Micromedex Healthcare Series [Database Online]. Truven Health Analytics; 2020. Accessed June 4, 2020.
55.
Active ingredient: Teriparatide. RED BOOK Online. Micromedex Healthcare Series [Database Online]. Truven Health Analytics; 2020. Accessed June 4, 2020.
56.
Active ingredient: Romosozumab. RED BOOK Online. Micromedex Healthcare Series [Database Online]. Truven Health Analytics; 2020. Accessed June 4, 2020.
